Research shows genetic variants significantly affect the weight loss outcomes of popular GLP-1 receptor agonists, including Mounjaro and Ozempic, suggesting personalized medicine may enhance treatment effectiveness.
In a pivotal study published in the journal Nature, researchers have found that the effectiveness of weight loss medications may be closely linked to genetic factors. This research, involving nearly 28,000 participants using weight loss drugs that mimic natural hormones regulating appetite and metabolism, adds a new dimension to understanding the variability in treatment responses among individuals.
Weight loss medications such as semaglutide, known commercially as Ozempic and Wegovy, and tirzepatide, marketed as Mounjaro, have been hailed as significant advancements in managing obesity and diabetes. However, patient responses to these drugs have varied widely, with some individuals experiencing substantial weight loss while others report negligible effects.
The Study and Its Findings
The study was conducted by researchers at the 23andMe Research Institute, focusing on the genetic profiles of users of these medications. Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a hormone that influences appetite and insulin secretion. Tirzepatide takes this a step further by mimicking both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In clinical trials, participants taking semaglutide lost an average of 10% of their body weight, yet the results varied significantly; some individuals lost more than 25% while others lost little to no weight.
Researchers identified a specific genetic variant that impacts the binding of these drugs to the GLP-1 receptor. Individuals with one copy of this genetic variant lost an average of 0.76 kilograms more over a median treatment duration of eight months compared to those without the variant. Those with two copies of the variant showed an even greater weight loss, averaging 1.5 kilograms more.
Additionally, the study found correlations between this genetic variant and the severity of side effects, such as nausea and vomiting, particularly in patients using tirzepatide, which was associated with a higher risk of these adverse effects.
Implications for Diverse Populations
The findings hold significant implications for diverse populations, particularly in India, where obesity is a growing concern. Dr. Anoop Misra, Chairman at Fortis CDOC Hospital for Diabetes and Allied Sciences in New Delhi, emphasized that genetic variability plays a crucial role in weight loss outcomes. He noted that prior research in Indian populations indicated that genetic variants, including those in the FTO and VDR genes, significantly affect responses to dietary interventions and weight loss therapies.
Dr. Misra mentioned, “The present study strengthens this evidence with more robust data,” highlighting the need for further studies in Indian populations to explore whether genetic profiling can personalize obesity treatment. He advocates for research aimed at identifying individuals who are most likely to benefit from specific weight-loss therapies, thereby enhancing treatment efficacy.
Dr. V Mohan, Chairman of Dr. Mohan’s Diabetes Specialities Centre in Chennai, has also observed varied responses among his patients using earlier GLP-1 medications, such as liraglutide. He categorized patients into four groups based on their responses: super responders (those who experienced significant weight loss and reduced blood sugar levels), partial responders (who saw only a decrease in blood sugar), non-responders (who experienced no change), and a small group that did not respond to treatment.
Dr. Mohan has been exploring the genetic connections to these responses, referring to the field of pharmacogenomics, which studies how an individual’s genetic makeup influences their response to drugs. He noted that understanding these genetic factors can help healthcare providers determine the most effective medications and dosages for their patients.
The Need for Further Research
While this study marks a significant step in understanding the genetic influence on drug efficacy, Dr. Mohan warned that more research is necessary to gauge how drug effectiveness may vary among different ethnicities, genders, and age groups. He pointed out that certain populations, such as those with Insulin Resistant Obese Diabetes (IROD), may respond better to weight loss drugs compared to those with insulin-deficient Type 2 diabetes.
Dr. Mohan also highlighted the potential of alternative medications that work by preventing the breakdown of gut hormones rather than mimicking them, suggesting that these may be more effective for South Asian populations. He called for more studies to evaluate the efficacy of weight loss drugs among South Asians, emphasizing the need for tailored approaches in obesity treatment.
As the landscape of obesity treatment continues to evolve, the integration of genetic insights into clinical practice may pave the way for more personalized and effective weight loss strategies, offering hope to many who struggle with obesity and related health issues.
No Comment! Be the first one.